Zhitong Finance App learned that innovative drug concept stocks continued to rise. As of press release, Keji Pharmaceutical-B (02171) rose 10.3% to HK$5.57; Laikai Pharmaceutical-B (02105) rose 9.15% to HK$6.44; Rongchang Biotech (09995) rose 6.29% to HK$31.25; and Junshi Biotech (01877) rose 5.65% to HK$10.28.

Yongxing Securities pointed out that the health insurance fund is generally running smoothly in 2023. The bank believes that with the establishment of an innovative drug support mechanism covering the entire process of declaration, review, calculation, and negotiation, more new drugs and good drugs are expected to be included in medical insurance, and enterprises related to innovative drug research and development are expected to benefit. Donghai Securities said that since this year, including clear support for innovative drugs and continuous optimization of procurement renewal terms, etc., there has been a clear positive trend in industry policy; the overall sector is expected to continue to warm up after the second quarter.